Peer-reviewed veterinary case report
Masitinib treatment results for advanced melanoma in dogs
By Giuliano, A & Dobson, J·Published in The Journal of small animal practice·2020·*Department of Veterinary Medicine, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma.
- Species:
- dog
Plain-English summary
A group of 17 dogs with advanced malignant melanoma (a type of skin cancer) were treated with a medication called masitinib mesylate after their owners chose not to pursue traditional treatments. While two dogs showed some improvement and seven had stable disease, eight dogs continued to experience tumor growth. On average, the dogs survived about 119 days after starting treatment. Although masitinib was generally well-tolerated, some dogs experienced mild side effects like anemia and diarrhea. Overall, this treatment showed limited effectiveness for dogs with advanced melanoma.
People also search for: dog melanoma treatment · masitinib for dogs · advanced skin cancer in dogs · dog cancer survival time · side effects of masitinib in dogs
Abstract
OBJECTIVE: To investigate efficacy of masitinib mesylate for the treatment of advanced malignant melanoma in dogs. MATERIALS AND METHODS: Prospective clinical trial on 17 dogs with stage III and IV malignant melanoma (two digital, one anal and 14 oral mucosal). Only dogs with advanced gross disease for which the owner declined conventional treatment or dogs with progressive tumour despite conventional treatment were included. RESULTS: There was a partial response in two dogs, stable disease in seven and tumour progression in eight dogs. Median survival time for all 17 dogs was 119 days (range 21-255). Masitinib was generally well-tolerated but grade 2 anaemia, grade 1 neutropenia, grade 1 diarrhoea and grade 2 anorexia were observed in one dog each. CLINICAL SIGNIFICANCE: There was only mild effectiveness in end-stage disease, indicating that masitinib mesylate is not an appropriate sole-agent option for treatment of advanced malignant melanoma in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31960455/